bispecific CD19/CD22 CAR T-cell therapy （University of Colorado）

N/A

Report date: 2022/07/12 13:56:33

Base Information

Drug Namebispecific CD19/CD22 CAR T-cell therapy （University of Colorado）

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD22

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Colorado

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Colorado

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A